Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ​by 59% after five years of follow-up, data from ‌a mid-stage trial showed Thursday.

The U.S. FDA said on Thursday it would hold a meeting of outside experts next ​month to review Moderna's experimental flu shot.

Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement.

Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.

The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.

Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.